Skip to main content
Healthcare

STAT+: Lilly says ‘triple-G’ drug beats Novo’s Ozempic in diabetes study

STAT+: Lilly says ‘triple-G’ drug beats Novo’s Ozempic in diabetes study

Feed excerpt — reported by STAT News

New data add to expectations that retatrutide will be one of Lilly’s greatest growth drivers.

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →

Original Source

This article was syndicated from STAT News. All rights remain with the original publisher.